Serial #79331576
LIVE

Add to watchlist:

No watchlists yet
View on USPTO

Serial #79331576 Trademark

Serial Number: 79331576 • Registration: 7057765

Serial #79331576 is a trademark filed by ZHUZHOU QIANJIN PHARMACEUTICAL CO., LTD. on October 26, 2021. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently registered and active.

Owner Contact Info

ZHUZHOU QIANJIN PHARMACEUTICAL CO., LTD.

No. 801, Zhuzhou Avenue,

Entity Type: 99

Trademark Details

Filing Date

October 26, 2021

Registration Date

May 23, 2023

Published for Opposition

March 7, 2023

Filing History

FINAL DECISION TRANSACTION PROCESSED BY IB
Sep 17, 2023 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Aug 25, 2023 FICS
FINAL DISPOSITION PROCESSED
Aug 25, 2023 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Aug 23, 2023 FICR
NOTICE OF REGISTRATION CONFIRMATION EMAILED
May 23, 2023 NRCC
REGISTERED-PRINCIPAL REGISTER
May 23, 2023 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Mar 7, 2023 NPUB
PUBLISHED FOR OPPOSITION
Mar 7, 2023 PUBO
NOTIFICATION PROCESSED BY IB
Mar 6, 2023 GPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Feb 15, 2023 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Feb 15, 2023 OP2R
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Feb 15, 2023 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jan 31, 2023 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jan 30, 2023 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jan 29, 2023 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jan 29, 2023 TROA
REFUSAL PROCESSED BY IB
Oct 25, 2022 RFNP
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Oct 1, 2022 RFCS
REFUSAL PROCESSED BY MPU
Sep 30, 2022 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Aug 10, 2022 RFCR
NON-FINAL ACTION WRITTEN
Aug 9, 2022 CNRT
ASSIGNED TO EXAMINER
Aug 3, 2022 DOCK
APPLICATION FILING RECEIPT MAILED
Feb 4, 2022 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jan 31, 2022 NWOS
LIMITATION FROM ORIGINAL APPLICATION ENTERED
Jan 28, 2022 LIMI
SN ASSIGNED FOR SECT 66A APPL FROM IB
Jan 20, 2022 REPR